| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 26.33 | 1.9% | 21.5% |
| Total Income | 26.33 | 1.9% | 21.5% |
| Expenditure | 23.39 | 9.6% | 0.9% |
| PBT | — | ||
| Net Profit | -30.41 | 1412.9% | 963.3% |
| OPM | 11.17% | 11.29pp | 20.05pp |
| NPM | — | ||
| EPS | -3.52 | 1430.4% | 935.3% |
Sanara MedTech Inc. Reports Q3 2025 Revenue Up 22% Y-o-Y
04 May 2026 · 4 May, 7:23 am
Summary
Sanara MedTech Inc. reported a strong third quarter in 2025, with net revenue increasing by 22% to $26.3 million. The company achieved net income from continuing operations of $0.8 million, a significant improvement from the net loss of $0.2 million in the same quarter of the previous year. Adjusted EBITDA also saw a substantial increase, reaching $4.9 million. The company strategically realigned its portfolio by ceasing operations of Tissue Health Plus to focus on its core surgical business, which contributed to the overall positive financial results.
Key Highlights
- 1
Sanara MedTech Inc. reported a 22% increase in net revenue to $26.3 million for the third quarter of 2025, compared to $21.7 million in the third quarter of 2024.
- 2
Net income from continuing operations was $0.8 million in Q3 2025, compared to a net loss of $0.2 million in Q3 2024.
- 3
Adjusted EBITDA for the third quarter of 2025 increased to $4.9 million, compared to $2.6 million in the third quarter of 2024.
- 4
Net revenue for the first nine months of 2025 increased by 25% to $75.6 million, compared to $60.4 million in the first nine months of 2024.
- 5
The company ceased operations of Tissue Health Plus (THP) to improve operating efficiency and reallocate resources to its core surgical business.
- 6
Sales of surgical soft tissue products, including CellerateRX® Surgical and BIASURGE®, increased by 24% in Q3 2025.
Management Comments
Seth Yon
Our surgical team delivered strong sales performance in the third quarter, culminating in net revenue growth of 22% year-over-year. Our net revenue growth was fueled by a 24% increase in sales of our surgical soft tissue products, including CellerateRX® Surgical and BIASURGE®. This performance reflects the success of our commercial strategy to develop relationships with independent distributors, expand into new healthcare facilities, and penetrate existing facilities by adding new surgeon users. In addition, we achieved notable year-over-year improvements in our profitability profile, with a $1.0 million improvement in net income from continuing operations and a $2.3 million improvement in Adjusted EBITDA, on net revenue growth of $4.7 million year-over-year. Regarding THP, as outlined in our press release yesterday, we have completed a thorough assessment of strategic alternatives for THP and initiated a realignment of our portfolio in the third quarter. Accordingly, we have ceased THP’s operations to enhance operational efficiency and allocate resources to our core surgical business. We believe this focus will support sustained long-term growth and value creation. For the remainder of 2025, our team will continue to execute our commercial plan, improve our operational efficiency, and invest wisely in our surgical business. We expect these efforts to support strong, sustainable revenue growth and improved profitability, both this year and beyond.
Informational and educational content only. Not investment advice.